Re: Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression among Men with Early-Stage Prostate Cancer: The MEAL Randomized Clinical Trial.
Re: Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT).
Clinical Outcomes in Men of Diverse Ethnic Backgrounds with Metastatic Castration Resistant Prostate Cancer.
We have shown previously in multivariable analysis that black men had 19% lower risk of death than white men with metastatic castration resistant prostate cancer (mCRPC) treated with a docetaxel […]» Read more
The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial.
External beam radiotherapy (EBRT) with neoadjuvant/adjuvant androgen deprivation therapy (ADT) is an established treatment option to prolong survival for patients with intermediate- and high-risk prostate cancer (PCa). Relugolix, an oral […]» Read more
Association of Early Palliative Care Use with Survival and Place of Death among Patients with Advanced Lung Cancer Receiving Care in the Veterans Health Administration.
Bladder Preservation with Twice-a-Day Radiation plus Fluorouracil/Cisplatin or Once Daily Radiation plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial.
Health-Related Quality of Life of Patients with Bladder Cancer in the RAZOR Trial – A Multi-Institutional Randomized Trial Comparing Robot versus Open Radical Cystectomy.
To evaluate health-related quality of life following robotic and open radical cystectomy as a treatment for bladder cancer.Using the Randomized Open versus Robotic Cystectomy (RAZOR) trial population we assessed health-related […]» Read more
External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node Dissection.
The 2019 Briganti nomogram was developed to calculate the risk of lymph node invasion (LNI) and identify prostate cancer (PCa) patients diagnosed with magnetic resonance imaging (MRI)-targeted biopsy who should […]» Read more
Hypermethylation of FOXA1 and Allelic Loss of PTEN Drive Squamous Differentiation and Promote Heterogeneity in Bladder Cancer.
Downgrading from Biopsy Grade Group 4 Prostate Cancer in Patients Undergoing Radical Prostatectomy for High or Very High Risk Prostate Cancer.
To examine rates of Grade Group (GG) 4 downgrading at radical prostatectomy (RP) among men diagnosed with high (HR)- and very-high risk (VHR) prostate cancer (PCa) at biopsy.A pooled cohort […]» Read more
Urine Extracellular Vesicle GATA2 mRNA Discriminates Biopsy Result in Men with Suspicion of Prostate Cancer.
PSA has limited performance in detecting prostate cancer (PCa). The transcription factor GATA2 is expressed in aggressive PCa. Here we analyzed the predictive value of urine extracellular vesicle (EV) GATA2 […]» Read more
PSA and PSA Doubling Time Predict Findings on 18F-DCFPyL PET/CT in Patients with Biochemically-Recurrent Prostate Cancer.
PSMA-targeted 18F-DCFPyL PET/CT may offer superior image quality and sensitivity for the detection of biochemically-recurrent prostate cancer. In this study, we examine the association of Gleason sum, serum prostate specific […]» Read more
Postdiagnosis Body Mass Index, Weight Change, and Mortality From Prostate Cancer, Cardiovascular Disease, and All Causes Among Survivors of Nonmetastatic Prostate Cancer.
To investigate the association of postdiagnosis body mass index (BMI) and weight change with prostate cancer-specific mortality (PCSM), cardiovascular disease-related mortality (CVDM), and all-cause mortality among survivors of nonmetastatic prostate […]» Read more
5α-Reductase inhibitors (5ARI) reduced risk of prostate cancer (Pca) with 25% in two randomized trials but increased risk of Gleason 8-10 at biopsy. One explanation is that 5ARI induce morphological […]» Read more
Recently developed clinical guidelines suggest that men in families with specific cancer syndromes, such as hereditary breast and ovarian cancer (HBOC), consider genetic testing, especially in the setting of aggressive […]» Read more
A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer.
Activation of the PI3K/AKT/mTOR pathway through loss of phosphatase and tensin homolog (PTEN) occurs in approximately 50% of patients with metastatic castration-resistant prostate cancer (mCRPC). Recent evidence suggests that combined […]» Read more
Short-Term Outcomes of Active Surveillance for Low-Risk Prostate Cancer Among Men with Germline DNA Repair Gene Mutations.
Men with germline mutations in DNA-repair genes have a higher risk of developing prostate cancer. Active surveillance (AS) is the preferred treatment modality for low-risk prostate cancer. However, many fear […]» Read more
Expression of Small Non-coding RNAs in Urinary Exosomes Classifies Prostate Cancer into Indolent and Aggressive Disease.
This is the first report of the development and performance of a platform that interrogates small non-coding RNAs (sncRNA) isolated from urinary exosomes (the miR Sentinel™ Tests): the Sentinel™ PCa […]» Read more
Cost-Effectiveness of Maintenance BCG for Intermediate and High Risk Non-Muscle Invasive Bladder Cancer.
While guidelines support the use of maintenance BCG(mBCG) for patients with intermediate- and high-risk non-muscle invasive bladder cancer(NMIBC), in an era of BCG shortage we explored the cost-effectiveness of mBCG.A […]» Read more
The Challenges of Bacillus of Calmette-Guerin (BCG) Therapy for High Risk Non Muscle Invasive Bladder Cancer Treatment in Older Patients.
Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance.
Surgical Complications in Postchemotherapy Retroperitoneal Lymph Node Dissection for Nonseminoma Germ Cell Tumour: A Population-Based Study from the Swedish Norwegian Testicular Cancer Group.
Hemigland Cryoablation of Localized Low, Intermediate and High Risk Prostate Cancer: Oncologic and Functional Outcomes at 5 Years.
Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review.
The optimal treatment for men with high-risk localized or locally advanced prostate cancer (PCa) remains unknown.To perform a systematic review of the existing literature on the effectiveness of the different […]» Read more